Abstract: Techniques for implementing organic materials in sunscreen applications are provided herein. A method includes selecting a combination of multiple organic materials to incorporate into a sunscreen composition, wherein said selecting is based on (i) a desired absorption spectrum of the sunscreen composition, (ii) the absorption spectrum of each of the multiple organic materials, and (iii) a particle size limitation for each of the multiple organic materials, and incorporating the selected combination of organic materials into the sunscreen composition to generate the desired absorption spectrum. A composition includes a combination of multiple organic materials incorporated into a sunscreen composition, wherein the combination of organic materials is selected based on (i) a desired absorption spectrum of the sunscreen composition, (ii) the absorption spectrum of each of the multiple organic materials, and (iii) a particle size limitation for each of the multiple organic materials.

Abstract: A cosmetic composition for dyeing keratinous fibers is provided herein. The cosmetic composition includes water and from about 6 to about 12 wt % organic solvent relative to the weight of the composition. The organic solvent includes from about 80 to about 100 wt % propylene carbonate and from about 0 to about 20 wt % benzyl alcohol. The cosmetic composition has a pH value in the range from about 1.0 to about 5.5 and at least one acid directly absorbed dye.

Abstract: The invention provides a hair shaping composition suitable for topical application to hair, the composition having a pH of 4 or less and comprising, in an aqueous continuous phase: (i) at least 0.5% (by weight based on the total weight of the composition) of one or more polyhydroxy acid lactones; (ii) at least 0.5% (by weight based on the total weight of the composition) of one or more aliphatic di- or tricarboxylic acids, and (iii) at least 0.1% (by weight based on the total weight of the composition) of glyoxylic acid or a salt or hydrate thereof.

Abstract: Provided are a cosmetic composition for preventing or ameliorating a ultraviolet-induced skin damage including mitochondria-targeted vitamin E as an active ingredient, as well as a method for protecting skin from ultraviolet-induced skin damage or for ameliorating an ultraviolet-induced skin damage using the same compound.

Abstract: Described are personal care compositions, comprising water, nonionic cellulose ethers having hydroxyethyl groups and being further substituted with one or more hydrophobic substituents, and at least one hair fixative polymer, moisturizer, conditioner, humectant, cationic conditioning polymer, antioxidant, anti-aging active, or sun care active.

Abstract: This method includes the provision of a first fluid (36) including the first phase and a first precursor polymer of the coacervate contained in the first phase, and the formation of drops of the first fluid (36) in a second fluid (40) intended to form the second phase (16). It includes the steps of introducing a second precursor polymer of the coacervate into the second fluid (40) and, during the formation of each drop (12), or once each drop (12) has been formed, for generating the coacervate layer by interaction between the first precursor polymer and the second precursor polymer at the interface between the first phase (14) and the second phase (16).

Abstract: The present invention relates to a composition for dyeing keratin fibers, comprising a) at least one oxidation dye precursor, b) at least one anionic associative polymer i), c) at least one anionic non associative polymer ii), and d) at least one anionic surfactant. The composition optionally contains alkaline agent.

Abstract: The present invention relates to a water-based cosmetic wherein a hydrophobic powder is directly dispersed in the water phase of the water-based cosmetic, the water-based cosmetic having the excellent smoothness, water resistance and cosmetic durability characteristic of hydrophobic powders, while maintaining the refreshing sensation of use that is inherent in water-based cosmetics. The invented water-based cosmetic is characterized by comprising: (A) 0.1 to 5 mass % of a polyether-modified silicone having an HLB (Si) of 5 to 14; (B) one or more hydrophilic thickeners; (C) a polyol and/or an ethyl alcohol; and (D) one or more hydrophobic powders chosen from among metal oxides hydrophobically treated without using a metal soap, hydrophobic organic powders and silicone powders; wherein the (D) hydrophobic powder is dispersed in the water phase.

Abstract: Disclosed are compositions and methods for their use for reducing tumor necrosis factor alpha (TNF-?) and/or vascular endothelial growth factor (VEGF) production in skin cells by topically applying to skin in need thereof, a composition comprising an effective amount of Opuntia ficus-indica tuna, Opuntia ficus-indica nopales, or both, or extracts thereof, to reduce TNF-? or VEGF production in skin cells.

Abstract: Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.

Abstract: Methods and devices for three-dimensional navigation of magnetic nanoparticles are provided. A method can comprise introducing high-anisotropy magnetic nanoparticles to a mammal and directing the high-anisotropy magnetic nanoparticles towards a target region of the mammal. Direction control is achieved by subjecting the high-anisotropy magnetic nanoparticles to an alternating signal comprising a uniform magnetic field pulse having a strength greater than a coercivity of the high-anisotropy magnetic nanoparticles and a magnetic gradient pulse having a highest strength that is less than the coercivity of the high-anisotropy magnetic nanoparticles and a location of a lowest strength at the target region of the mammal, and the direction of the uniform magnetic field pulse being in an opposite direction of the magnetic gradient pulse.

Abstract: The invention relates to a topical veterinary composition for animals. It is characterized in that it comprises, in a physiologically acceptable medium, extracts of boldo Peumus boldus and extracts of meadowsweet Spiraea ulmaria. The invention applies in particular to preventing or treating or to assisting with the control of microbial infections.

Abstract: The invention relates to methods for the intra-amniotic administration of EDA agonists, in particular EDI200. Use of the methods described allow for the design of targeted therapeutic dosing and administration regimens in order to correct or alter abnormal phenotypes associated with ectodermal dysplasias, in particular, XLHED.

Abstract: An implant for insertion through a punctum and into a canalicular lumen of a patient. The implant includes a matrix of material, a therapeutic agent dispersed in the matrix of material, a sheath disposed over a portion of the matrix of material and configured to inhibit the therapeutic agent from being released from the matrix of material into the canalicular lumen and to allow the therapeutic agent to be released from a surface of the matrix of material to a tear film, and a retention structure configured to retain the implant within the canalicular lumen.

Abstract: The present invention relates to a homogeneous, stable, and palatable pharmaceutical solution comprising baclofen, sorbitol and naltrexone.

Abstract: Described herein are compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic.

Abstract: A medicament for treating cystitis and a method of treatment are provided. An agent to repair the damaged glycosaminoglycan (“GAG”) layers lining the urothelium, noted in cystitis, such as pentosan polysulfate, hyaluronic acid, chondroitin, etc., is provided in a liposomal carrier. Cystitis is treated by intravesically administering to a patient a therapeutically effective dose of the medicament.

Abstract: This invention provides compositions for making a solid lyophile of one or more nucleic acid active agents, which can be reconstituted as a drug product. The composition can include an aqueous suspension of lipid nanoparticles in a pharmaceutically acceptable solution, wherein the lipid nanoparticles encapsulate one or more nucleic acid active agents, a dextrin compound, and a saccharide compound. The nucleic acid active agents can be RNAi molecules capable of mediating RNA interference, as well as other RNAs and oligonucleotides.

Abstract: This invention is directed to a biodegradable, semi-crystalline, phase separated thermoplastic multi-block copolymer, a process for preparing said multi-block copolymer, a composition for the delivery of at least one biological active compound, and to a method for delivering a biologically active compound to a subject in need thereof. A multi-block copolymer of the invention is characterized in that: a) it comprises at least one hydrolysable pre-polymer (A) segment and at least one hydrolysable pre-polymer (B) segment, b) said multi-block copolymer having a Tg of 37° C. or less and a Tm of 110-250° C. under physiological conditions; c) the segments are linked by a multifunctional chain-extender; d) the segments are randomly distributed over the polymer chain; e) at least part of the pre-polymer (A) segment is derived from a water-soluble polymer.

Abstract: The present invention relates to a pharmaceutical calcium acetate formulation and a process for making the same. In particular, the present invention relates to a calcium acetate capsule formulation comprising granules comprising calcium acetate along with other formulation adjuvants contained within a pharmaceutically acceptable capsule.

Abstract: The present invention provides an intraorally rapidly disintegrating tablet that can be formed using an ordinary apparatus, that has hardness with no practical problem and that disintegrates rapidly with good feeling in the oral cavity. The present invention is intraorally rapidly disintegrating tablet produced by compression molding of a granule coated with a disintegrant, in which the granule contains a disintegrant also inside thereof and a drug except ambroxol hydrochloride inside and/or outside thereof.

Abstract: Nanoparticle delivery systems for use in targeting biologically active agents to the central nervous system comprise a composition comprising (a) a nanoparticle comprising: (i) a core comprising a metal and/or a semiconductor; and (ii) a corona comprising a plurality of ligands covalently linked to the core, wherein said ligands comprise a carbohydrate, insulin and/or a glutathione; and (b) the at least one agent to be delivered to the CNS. Methods of treatment and diagnosing CNS disorders utilizing the nanoparticle delivery systems and related screening methods are also disclosed.

Abstract: A non-covalently assembled hydrogel or organo-gel composition with serum stability is described. Low molecular weight (<2,500 Da), generally regarded as safe (GRAS), materials assemble in the presence of a stabilizing agent at an appropriate molar percentage, forming hydrogel or organo-gel with nanostructures that resist disassembly or destabilization in serum for an extended period of time. The composition is used to deliver one or more therapeutic, prophylactic, or diagnostic agents, allowing for controlled release in response to biological stimuli such as enzymes and a greatly improved dosing efficacy.

Abstract: Proteinoid compounds characterized by a molecular weight (Mw) of at least 15,000 Da, processes of preparing such compounds and methods of use thereof, are provided. A method of monitoring the presence and metastases of cancer in a body of an individual is further disclosed.

Abstract: A transdermal delivery system for systemic delivery of donepezil is described, where the system comprises an adhesive matrix drug reservoir layer comprised of a copolymer of acrylic acid/vinyl acetate, triethyl citrate, and donepezil base generated in situ by reaction of donepezil HCl and an alkaline salt. The system is provided for treatment of Alzheimer's disease, and achieves transdermal delivery of the therapeutic agent at steady state that is bioequivalent to administration of the therapeutic agent orally.

Abstract: Provided is a use of dihydroxyacetone in the preparation of a medicament, the medicament being used for treating a cancer.

Abstract: The present invention relates to compositions and methods of treating warts and other human papilloma virus (HPV) skin infections. The present invention relates to compositions and methods of treating skin cancer.

Abstract: The invention relates to a composition for enhancing wound healing and/or for reducing pain and inflammation, comprising a first active ingredient and a second active ingredient, wherein the first active ingredient comprises an antiseptic and the second active ingredient comprises an admixture of at least one vitamin, at least one mineral and at least one amino acid, and to use of the composition for enhancing wound healing.

Abstract: An organ protectant solution which is intravenously administered includes at least one oncotic agent and optionally a high concentration of cell-impermeant molecules. Together, they promote transfer of water from cells to interstitium and into the capillaries, thereby preventing or reducing cell swelling, maintaining blood circulation and oxygenation of tissues, and extending the “Golden Hour” for traumatic and/or hemorrhagic shock patients. In addition, compositions comprising PEG-20k and methods of their use for preserving and/or reanimating harvested organs ex vivo for lengthy periods of time (e.g. at least about 8-24 hours) are also provided.

Abstract: A traditional Chinese medicine composition and preparation thereof for treating cardiovascular diseases is provided. The traditional Chinese medicine composition consists of: by weight percentage, phenolic acid derivatives 30%˜80%, tanshinones 2%˜10% and saponins 15%˜60%.

Abstract: The present invention provides methods and compositions for the treatment of neuropathic pain. In certain embodiments, compositions comprising an dextromethorphan (or other N-methyl-D-aspartate receptor antagonist), tramadol, and gabapentin can synergistically act to reduce pain in a human patient. Pharmaceutical compositions may also comprise a capsaicinoid, an esterified capsaicinoid, and/or a tricyclic antidepressant.

Abstract: The present invention provides a simple and improved dosage form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABAB receptor agonist.

Abstract: The invention features a pharmaceutical suspension containing drug particles, a drug delivery device anchored in the mouth for continuously administering the pharmaceutical suspension, and methods of their use.

Abstract: The present invention provides dietary formulations comprising polyunsaturated fatty acids and vitamin E. The present invention further provides methods of treating various conditions, generally involving administering to an individual in need thereof an effective amount of a subject dietary formulation.

Abstract: The present invention relates to homogeneous formulations comprising omega-3 polyunsaturated fatty acids (n-3 PUFA) and resveratrol for oral administration, in which the resveratrol is solubilized in a solvent system consisting of omega-3 polyunsaturated fatty acids (n-3 PUFA), or their alkyl esters, and a ionic emulsifier. The composition according to the present invention can be formulated as food or nutritional supplement or medicament in the prevention or treatment of cardiovascular diseases due to lipid metabolism disorders and increased platelets aggregation, as well as damages due to free radicals and/or viral diseases.

Abstract: Provided herein are compositions and methods for treating and preventing lung injury (e.g. ventilation induced lung injury). In particular, the invention relates to compositions and methods for treating and preventing airway disease by activating the NRF2 pathway.

Abstract: This invention is directed to substituted acylanilide compounds and uses thereof in treating muscular dystrophies such as Duchenne muscular dystrophy and Becker muscular dystrophy and in improving or preserving lung function and cardiac function in a subject suffering from Duchenne muscular dystrophy.

Abstract: A combination of N-acetyl-L-cysteine, selenium in the form of selenomethionine and melatonin, and a medical product or pharmaceutical composition comprising such combination, useful for the treatment of a variety of diseases and conditions is described. The combination of N-acetyl-L-cysteine, selenium in the form of selenomethionine and melatonin is also useful for cosmetic treatment of skin and as an antibacterial agent.

Abstract: Disclosed herein are ferric citrate-containing tablets. In various embodiments, the tablets include ferric citrate formulations that meet certain dissolution, tableting and disintegration standards. In various aspects, the tablet formulations can include ferric citrate as the active ingredient and a binder. The formulations also can include a lubricant and/or a disintegrant (which, in some embodiments, can be the same as the binder).

Abstract: Provided is a pharmaceutical formulation and a method associated therewith for treating inflammation. The pharmaceutical formulation includes therapeutically effective amounts of sesquiterpenes such as ?-caryophyllene and two flavonoids. The two flavonoids include baicalin and catechin.

Abstract: Aqueous suspensions for oral administration are disclosed that include simvastatin having a d90 of simvastatin particles of less than about 100 ?m as the active agent. The aqueous suspension also includes simvastatin as about 20 mg to about 80 mg per 5 ml of the aqueous suspension, a suspending agent as about 20 mg to about 50 mg of the aqueous suspension, a wetting agent, an antimicrobial preservative, an antifoaming agent, water, and a buffering system providing the aqueous suspension with a pH of about 6.4 to about 7. Methods of making such a suspension and methods of treatments in orally administering the same are also disclosed.

Abstract: Methods of treating, managing or preventing liver disease are disclosed. Specific methods encompass the administration of apremilast, alone or in combination with additional active agents or treatment regimens.

Abstract: This document provides materials and methods related to bacterial compositions containing at least one bacterial organism having tryptophan decarboxylase activity. For example, bacterial compositions containing at least one bacterial organism having tryptophan decarboxylase activity and methods for using such bacterial compositions to improve gastrointestinal epithelial function and/or to treat gastrointestinal disorders are provided.

Abstract: Amorphous methyl((1S)-1-(((2S)-2-(5-(4?-(2-((2S)-1-((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-5-yl)-4-biphenylyl)-1H-imidazol-2-yl)-1-pyrrolidinyl) carbonyl)-2-methylpropyl) carbamate free base, amorphous methyl((1S)-1-(((2S)-2-(5-(4?-(2-((2S)-1-((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-5-yl)-4-biphenylyl)-1H-imidazol-2-yl)-1-pyrrolidinyl) carbonyl)-2-methylpropyl) carbamate dihydrochloride, methods of making them, and pharmaceutical compositions containing them.

Abstract: A veterinary composition is disclosed and is based on anthelmintic compounds, particularly from the benzimidazole group, with delayed release properties, preferably in the form of granules or pellets, to be added to feed or feed supplements offered to ruminants in order to control eggs and larvae of helminths, preferably from the genus Haemonchus spp.

Abstract: The present invention relates to pharmaceutical compositions useful for administration for treating, preventing, or reducing the risk of microbial infections.

Abstract: The present invention relates to crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid, pharmaceutical compositions and dosage forms comprising the crystalline forms, methods of making the crystalline forms and methods for their use for the treatment, prevention or management of diseases ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay.

Abstract: The invention relates to a compound comprising the following general formula (1) for use in the treatment of psychiatric or neurological disorders and inflammation, in particular neuroinflammation: (1) wherein each of R1, R2 and R3 are selected independently from each other from alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, aryl, heterocycle or heteroaryl.

Abstract: Myeloid differentiating agents can be used in the treatment of myeloid proliferative disorders.

Abstract: The invention relates to a novel salt of cytisine and pharmaceutical compositions comprising that salt. In particular, the invention relates to a succinate salt of cytisine which displays improved excipient compatibility, permitting the preparation of stable pharmaceutical compositions.